| 國立成功大學 |
2022 |
Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection
|
Huang, Y.-S.;Tseng, S.-Y.;Chen, W.-W.;Chang, T.-T.;Peng, C.-Y.;Lo, G.-H.;Hsu, C.-W.;Hu, C.-T.;Huang, Y.-H. |
| 國立成功大學 |
2022 |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
|
Chen, Y.-C.;Chang, T.-S.;Chen, Chen C.-H.;Cheng, P.-N.;Lo, C.-C.;Mo, L.-R.;Chen, Chen C.-T.;Huang, C.-F.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L.;investigators, on behalf of TACR |
| 國立成功大學 |
2022 |
Sofosbuvir/Velpatasvir for Hepatitis�C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, P.-N.;Mo, L.-R.;Chen, Chen C.-T.;Chen, Chen C.-Y.;Huang, C.-F.;Kuo, H.-T.;Lo, C.-C.;Tseng, K.-C.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Chou, K.-H.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Cheng, Cheng C.-Y.;Tsai, M.-C.;Liu, C.-J.;Dai, C.-Y.;Lin, H.-C.;Kao, J.-H.;Chuang, W.-L.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
|
Liu, C.J.;Sheen, I.S.;Chen, Chen C.Y.;Chuang, W.L.;Wang, H.Y.;Tseng, K.C.;Chang, T.T.;Yang, J.;Massetto, B.;Suri, V.;Camus, G.;Jiang, D.;Zhang, F.;Gaggar, A.;Hu, T.H.;Hsu, Y.C.;Lo, G.H.;Chu, Chu C.J.;Chen, J.J.;Peng, C.Y.;Chien, R.N.;Chen, P.J. |
| 國立成功大學 |
2022 |
The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan
|
Lin, C.-L.;Tai, C.-M.;Huang, J.-F.;Liu, C.-J.;Chen, H.-F.;Cheng, P.-N.;Chen, Chen C.-Y.;Peng, C.-Y.;Wang, C.-C.;Weng, S.-H.;Tseng, Tseng T.-C.;Kao, J.-H. |
| 臺大學術典藏 |
2021-10-22T07:39:42Z |
Development and Psychometric Properties of the Taiwan Odd–Even Number Sequencing Test: A Nonalphabetic Measure of Working Memory
|
Chen Y.-T.; Peng C.-Y.; Hua M.-S.; Liu C.-C.; Chen H.-Y.; HAI-GWO HWU |
| 臺大學術典藏 |
2021-09-04T06:12:12Z |
Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease
|
Keating G.M.; Buti M.; Gadano A.; JIA-HORNG KAO; Lee C.-M.; Peng C.-Y.; Schiff E.R.; Tanwandee T. |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:52Z |
Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients
|
Yuan Q.; Song L.-W.; Liu C.-J.; Li Z.; Liu P.-G.; Huang C.-H.; Yan Y.; Ge S.-X.; Wang Y.-B.; Peng C.-Y.; Zhang J.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.; Xia N.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:52Z |
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion
|
Yang H.-C.; Chen C.-L.; Shen Y.-C.; Peng C.-Y.; Liu C.-J.; Tseng T.-C.; Su T.-H.; Chuang W.-L.; Yu M.-L.; Dai C.-Y.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:42Z |
Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na?ve Taiwanese patients with chronic hepatitis B
|
Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:39Z |
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study
|
Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
|
JIA-HORNG KAO; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues
|
Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
|
JIA-HORNG KAO; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus
|
Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:11Z |
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study
|
JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T06:10:54Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; JIA-HORNG KAO; Chen C.-C.; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; JIA-HORNG KAO; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T05:17:13Z |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
|
JIA-HORNG KAO; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. |
| 臺大學術典藏 |
2021-09-04T05:17:05Z |
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
|
Hsu C.-W.; Su W.-W.; Lee C.-M.; Peng C.-Y.; Chuang W.-L.; JIA-HORNG KAO; Chu H.-C.; Huang Y.-H.; Chien R.-N.; Liaw Y.-F. |
| 臺大學術典藏 |
2021-09-04T05:17:04Z |
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study
|
JIA-HORNG KAO; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J. |
| 臺大學術典藏 |
2021-09-04T05:16:59Z |
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan
|
Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO |
